These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 8491057)

  • 1. Cephalosporin-probenecid drug interactions.
    Brown GR
    Clin Pharmacokinet; 1993 Apr; 24(4):289-300. PubMed ID: 8491057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of probenecid on the pharmacokinetics of DQ-2556, a new 3-quaternary ammonium cephalosporin antibiotic, in humans.
    Shiba K; Yoshida M; Shimada J; Saito A; Matsubayashi K; Hashimoto S; Yoshida K; Osada Y; Sakai O
    Chemotherapy; 1992; 38(6):369-75. PubMed ID: 1288960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interference of selected second- and third-generation cephalosporins with creatinine determination.
    Guay DR; Meatherall RC; Macaulay PA
    Am J Hosp Pharm; 1983 Mar; 40(3):435-8. PubMed ID: 6846351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of probenecid administration on cephapirin pharmacokinetics and concentrations in mares.
    Juzwiak JS; Brown MP; Gronwall R; Houston AE
    Am J Vet Res; 1989 Oct; 50(10):1742-7. PubMed ID: 2802305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Probenecid: an unexplained effect on cephalosporin pharmacology.
    Welling PG; Dean S; Selen A; Kendall MJ; Wise R
    Br J Clin Pharmacol; 1979 Nov; 8(5):491-5. PubMed ID: 508557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic interactions of cefprozil with food, propantheline, metoclopramide, and probenecid in healthy volunteers.
    Shukla UA; Pittman KA; Barbhaiya RH
    J Clin Pharmacol; 1992 Aug; 32(8):725-31. PubMed ID: 1487562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implications of current recommendations for third-generation cephalosporin use in the WHO Western Pacific Region following the emergence of multiresistant gonococci.
    Tapsall JW
    Sex Transm Infect; 2009 Aug; 85(4):256-8. PubMed ID: 19261600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity, pharmacokinetics, clinical efficacy, safety and pharmacoeconomics of ceftriaxone compared with third and fourth generation cephalosporins: review.
    Bijie H; Kulpradist S; Manalaysay M; Soebandrio A
    J Chemother; 2005 Feb; 17(1):3-24. PubMed ID: 15828439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination.
    Ko H; Cathcart KS; Griffith DL; Peters GR; Adams WJ
    Antimicrob Agents Chemother; 1989 Mar; 33(3):356-61. PubMed ID: 2729930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and comparative pharmacology of cefoxitin and cephalosporins.
    Schrogie JJ; Rogers JD; Yeh KC; Davies RO; Holmes GI; Skeggs H; Martin CM
    Rev Infect Dis; 1979; 1(1):90-8. PubMed ID: 318227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pharmacokinetics of the third generation cephalosporins.
    Balant L; Dayer P; Auckenthaler R
    Clin Pharmacokinet; 1985; 10(2):101-43. PubMed ID: 3888488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of probenecid on the pharmacokinetics of moxalactam.
    DeSante KA; Israel KS; Brier GL; Wolny JD; Hatcher BL
    Antimicrob Agents Chemother; 1982 Jan; 21(1):58-61. PubMed ID: 6211135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects on the pharmacokinetics of intravenous ceftiofur sodium in dairy cattle of simultaneous intravenous acetyl salicylate (aspirin) or probenecid.
    Whittem T; Freeman DA; Hanlon D; Parton K
    J Vet Pharmacol Ther; 1995 Feb; 18(1):61-7. PubMed ID: 7752308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of cephalosporins with enhanced anti-anaerobic activity for treatment and prevention of anaerobic and mixed infections.
    DiPiro JT; May JR
    Clin Pharm; 1988 Apr; 7(4):285-302. PubMed ID: 3284692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of probenecid on the pharmacokinetics and distribution of cefoxitin in healthy volunteers.
    Reeves DS; Bullock DW; Bywater MJ; Holt HA; White LO; Thornhill DP
    Br J Clin Pharmacol; 1981 Apr; 11(4):353-9. PubMed ID: 7259928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacokinetics of ceftizoxime with and without probenecid].
    Adam D; Timmler R
    Arzneimittelforschung; 1982; 32(4):416-9. PubMed ID: 6285937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of dose doubling with probenecid for sustaining serum cefuroxime levels.
    Garton AM; Rennie RP; Gilpin J; Marrelli M; Shafran SD
    J Antimicrob Chemother; 1997 Dec; 40(6):903-6. PubMed ID: 9462447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Probenecid effect on cefuroxime pharmacokinetics in calves.
    Soback S; Ziv G; Kokue EI
    J Vet Pharmacol Ther; 1989 Mar; 12(1):87-93. PubMed ID: 2704066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of orally administered probenecid on the pharmacokinetics of cefoxitin.
    Vlasses PH; Holbrook AM; Schrogie JJ; Rogers JD; Ferguson RK; Abrams WB
    Antimicrob Agents Chemother; 1980 May; 17(5):847-55. PubMed ID: 7396472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal responses and pharmacokinetics of piretanide in humans: effect of route of administration, state of hydration and probenecid pretreatment.
    Noormohamed FH; McNabb WR; Dixey JJ; Lant AF
    J Pharmacol Exp Ther; 1990 Sep; 254(3):992-9. PubMed ID: 2395126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.